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Research in cardiovascular biology and disease is influenced by the chan-
ging landscape in biomedical and health research. Increased demands for
innovation, translation, and implementation of novel findings into patient
care are reflected in growthofpublications and journalswithmore clinical
and translational content, and more emphasis on the potential impact of
basic and preclinical research in basic science reports. At the same time
there has been an exciting growth of pure exploratory basic research,
related to technological innovation, e.g. advanced microscopy, rewarded
with the 2014 Nobel Prize.1 Novel concepts in cardiovascular biology
have increasingly been presented in multidisciplinary biology journals
such as Nature and Cell. This could potentially create dichotomy
between the basic science and clinical communities, further amplified by
concerns on a stagnating number of physician-scientists. Cardiovascular
Research has positioned itself as an overarching journal and wishes to
promote the dialogue and interaction between basic, translational, and
clinical research. In 2014 the journal published two focus and spotlight
issues that reflected this concept. The Spotlight Issue ‘Pregnancy-
mediated Heart & Vascular Disease’ highlighted both the clinical presen-
tation and clinical studies,2,3 and themechanistic concepts and insights.4–6
The Spotlight Issue ‘HDL Biology: New Insights in Metabolism, Function,
and Translation’, addressed the apparent failure of translation during ran-
domized studies of HDL-C raising approaches, despite substantial pro-
spective observational, in vitro and in vivo mechanistic studies supporting
the expected benefit. Expert reviews in this issue presented current
knowledge and new insights on the many functional roles of HDL and
their clinical relevance.7–16 A third Spotlight issue focused more on
novel mechanistic studies examining cell–cell interactions in the heart
in heart failure and ischaemic heart disease.17 In the beginning of 2015
the journal will publish a focus issue on sarcomeric cardiomyopathies
that again will span from clinical data to mechanistic studies and novel
bench approaches using patient-specific IPSCs (http://cardiovascres.
oxfordjournals.org/spotlight_issues.html). The journal will continue in
this track of providing a forum from research spanning from basic to clin-
ical, emphasizing the dialogue and translation.
The journalwill also followupon theconcernsof reliability and repro-
ducibility that may be involved in failure of translation.18 Further
improvements in data presentation and quality control will be part of
the updated instructions to authors and will be implemented during
the review process. Position papers from expert groups, such as on car-
dioprotection in cardiac ischaemia, can contribute to improve transla-
tion by better defining research approaches.19,20 The journal is open
to publishing viewpoints on research strategy and policy relevant to
cardiovascular research and more overarching issues.
In 2015 we continue our commitment to serve the scientific
community in cardiovascular research, authors, and reviewers. We
would like to thank all of you for your contributions. We wish to
thank particularly the editorial board members and editors-at-large
for their work in 2014. In 2015 we will welcome new editorial board
members to further support and improve the review process. With
Oxford University Press we are continuously working to improve
the journal, and we are very proud of our new website with enhanced
features for browsing and data access.We look forward to an exciting
2015!
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